Secukinumab improves patient-reported outcomes in ankylosing spondylitis

GLASGOW, SCOTLAND – Treatment with the anti–interleukin-17A monoclonal antibody secukinumab improved a range of patient-reported outcome measures in a phase III trial of patients with ankylosing...
Source: Rheumatology News - Category: Rheumatology Source Type: research